Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Models and Machines: How Deep Learning Will Take Clinical Pharmacology to the Next Level.

Hutchinson L, Steiert B, Soubret A, Wagg J, Phipps A, Peck R, Charoin JE, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2018 Dec 14. doi: 10.1002/psp4.12377. [Epub ahead of print]

2.

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.

Ribba B, Boetsch C, Nayak T, Grimm HP, Charo J, Evers S, Klein C, Tessier J, Charoin JE, Phipps A, Pisa P, Teichgräber V.

Clin Cancer Res. 2018 Jul 15;24(14):3325-3333. doi: 10.1158/1078-0432.CCR-17-2953. Epub 2018 Feb 20.

PMID:
29463551
3.

Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation.

Ribba B, Grimm HP, Agoram B, Davies MR, Gadkar K, Niederer S, van Riel N, Timmis J, van der Graaf PH.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):496-498. doi: 10.1002/psp4.12206. Epub 2017 Jul 11.

4.

Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.

Hutchinson LG, Mueller HJ, Gaffney EA, Maini PK, Wagg J, Phipps A, Boetsch C, Byrne HM, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):636-645. doi: 10.1002/psp4.12142. Epub 2016 Nov 14.

5.

Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions.

Lavielle M, Ribba B.

Pharm Res. 2016 Dec;33(12):2979-2988. Epub 2016 Sep 7.

PMID:
27604892
6.

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.

Tate SC, Andre V, Enas N, Ribba B, Gueorguieva I.

Eur J Cancer. 2016 Oct;66:95-103. doi: 10.1016/j.ejca.2016.07.009. Epub 2016 Aug 18.

PMID:
27544929
7.

Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.

Yankeelov TE, An G, Saut O, Luebeck EG, Popel AS, Ribba B, Vicini P, Zhou X, Weis JA, Ye K, Genin GM.

Ann Biomed Eng. 2016 Sep;44(9):2626-41. doi: 10.1007/s10439-016-1691-6. Epub 2016 Jul 6. Review.

8.

Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.

Ouerdani A, Goutagny S, Kalamarides M, Trocóniz IF, Ribba B.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1263-73. doi: 10.1007/s00280-016-3046-2. Epub 2016 May 4.

PMID:
27146400
9.

Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics.

Mazzocco P, Barthélémy C, Kaloshi G, Lavielle M, Ricard D, Idbaih A, Psimaras D, Renard MA, Alentorn A, Honnorat J, Delattre JY, Ducray F, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):728-37. doi: 10.1002/psp4.54. Epub 2015 Oct 10.

10.

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings.

Wilson S, Tod M, Ouerdani A, Emde A, Yarden Y, Adda Berkane A, Kassour S, Wei MX, Freyer G, You B, Grenier E, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):720-7. doi: 10.1002/psp4.12045. Epub 2015 Dec 11.

11.

Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.

Mazzocco P, Honnorat J, Ducray F, Ribba B.

Comput Math Methods Med. 2015;2015:297903. doi: 10.1155/2015/297903. Epub 2015 Dec 15.

12.

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma.

Ouerdani A, Struemper H, Suttle AB, Ouellet D, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2015 Nov;4(11):660-8. doi: 10.1002/psp4.12001. Epub 2015 Nov 3.

13.

Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue.

Stroh M, Carlile DJ, Li CC, Wagg J, Ribba B, Ramanujan S, Jin J, Xu J, Charoin JE, Xhu ZX, Morcos PN, Davis JD, Phipps A.

CPT Pharmacometrics Syst Pharmacol. 2015 Sep;4(9):495-7. doi: 10.1002/psp4.12014. Epub 2015 Sep 11.

14.

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development.

Swat MJ, Moodie S, Wimalaratne SM, Kristensen NR, Lavielle M, Mari A, Magni P, Smith MK, Bizzotto R, Pasotti L, Mezzalana E, Comets E, Sarr C, Terranova N, Blaudez E, Chan P, Chard J, Chatel K, Chenel M, Edwards D, Franklin C, Giorgino T, Glont M, Girard P, Grenon P, Harling K, Hooker AC, Kaye R, Keizer R, Kloft C, Kok JN, Kokash N, Laibe C, Laveille C, Lestini G, Mentré F, Munafo A, Nordgren R, Nyberg HB, Parra-Guillen ZP, Plan E, Ribba B, Smith G, Trocóniz IF, Yvon F, Milligan PA, Harnisch L, Karlsson M, Hermjakob H, Le Novère N.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):316-9. doi: 10.1002/psp4.57. Epub 2015 Jun 15.

15.

Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology.

Buil-Bruna N, Sahota T, López-Picazo JM, Moreno-Jiménez M, Martín-Algarra S, Ribba B, Trocóniz IF.

Cancer Res. 2015 Jun 15;75(12):2416-25. doi: 10.1158/0008-5472.CAN-14-2584. Epub 2015 May 4.

16.

The use of model-based tumor-size metrics to predict survival.

Ribba B, Holford N, Mentré F.

Clin Pharmacol Ther. 2014 Aug;96(2):133-5. doi: 10.1038/clpt.2014.111. No abstract available.

17.

Enabling multiscale modeling in systems medicine.

Wolkenhauer O, Auffray C, Brass O, Clairambault J, Deutsch A, Drasdo D, Gervasio F, Preziosi L, Maini P, Marciniak-Czochra A, Kossow C, Kuepfer L, Rateitschak K, Ramis-Conde I, Ribba B, Schuppert A, Smallwood R, Stamatakos G, Winter F, Byrne H.

Genome Med. 2014 Mar 21;6(3):21. doi: 10.1186/gm538. eCollection 2014. No abstract available.

18.

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

Ribba B, Holford NH, Magni P, Trocóniz I, Gueorguieva I, Girard P, Sarr C, Elishmereni M, Kloft C, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2014 May 7;3:e113. doi: 10.1038/psp.2014.12.

19.

A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.

Buil-Bruna N, López-Picazo JM, Moreno-Jiménez M, Martín-Algarra S, Ribba B, Trocóniz IF.

AAPS J. 2014 May;16(3):609-19. doi: 10.1208/s12248-014-9600-0. Epub 2014 Apr 17.

20.

Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy.

Ducray F, Kaloshi G, Houillier C, Idbaih A, Ribba B, Psimaras D, Marie Y, Boisselier B, Alentorn A, Dainese L, Navarro S, Mokhtari K, Sanson M, Hoang-Xuan K, Delattre JY.

J Neurooncol. 2013 Nov;115(2):261-5. doi: 10.1007/s11060-013-1224-1. Epub 2013 Aug 17.

PMID:
23955572
21.

Modeling tumor response after combined administration of different immune-stimulatory agents.

Parra-Guillen ZP, Berraondo P, Ribba B, Trocóniz IF.

J Pharmacol Exp Ther. 2013 Sep;346(3):432-42. doi: 10.1124/jpet.113.206961. Epub 2013 Jul 11.

PMID:
23845890
22.

Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies.

Parra-Guillen ZP, Berraondo P, Grenier E, Ribba B, Troconiz IF.

AAPS J. 2013 Jul;15(3):797-807. doi: 10.1208/s12248-013-9483-5. Epub 2013 Apr 19.

23.

A structural model of the VEGF signalling pathway: emergence of robustness and redundancy properties.

Lignet F, Calvez V, Grenier E, Ribba B.

Math Biosci Eng. 2013 Feb;10(1):167-84. doi: 10.3934/mbe.2013.10.167.

24.

Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.

Lignet F, Benzekry S, Wilson S, Billy F, Saut O, Tod M, You B, Adda Berkane A, Kassour S, Wei MX, Grenier E, Ribba B.

J Theor Biol. 2013 Mar 7;320:86-99. doi: 10.1016/j.jtbi.2012.12.013. Epub 2012 Dec 21.

PMID:
23261980
25.

Time-course analysis of main markers of primary infection in cats with the feline immunodeficiency virus.

Ribba B, El Garch H, Brunet S, Grenier E, Castiglione F, Poulet H, Vanhems P.

Comput Math Methods Med. 2012;2012:342602. doi: 10.1155/2012/342602. Epub 2012 Sep 25.

26.

A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy.

Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F.

Clin Cancer Res. 2012 Sep 15;18(18):5071-80. Epub 2012 Jul 3.

27.

Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance.

Emde A, Mahlknecht G, Maslak K, Ribba B, Sela M, Possinger K, Yarden Y.

Transl Oncol. 2011 Oct;4(5):293-300. Epub 2011 Oct 1.

28.

Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth.

Emde A, Pradeep CR, Ferraro DA, Ben-Chetrit N, Sela M, Ribba B, Kam Z, Yarden Y.

Oncogene. 2011 Apr 7;30(14):1631-42. doi: 10.1038/onc.2010.547. Epub 2010 Dec 6.

29.

A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers.

Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G.

Eur J Cancer. 2011 Feb;47(3):479-90. doi: 10.1016/j.ejca.2010.10.003. Epub 2010 Nov 10.

PMID:
21074409
30.

Computational analysis of the influence of the microenvironment on carcinogenesis.

Basanta D, Ribba B, Watkin E, You B, Deutsch A.

Math Biosci. 2011 Jan;229(1):22-9. doi: 10.1016/j.mbs.2010.10.005. Epub 2010 Oct 31.

PMID:
21044636
31.

Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.

You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Fléchon A.

Urology. 2010 Aug;76(2):423-9.e2. doi: 10.1016/j.urology.2010.02.049. Epub 2010 May 15.

PMID:
20472276
32.

Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.

You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F.

Ann Oncol. 2010 Aug;21(8):1643-50. doi: 10.1093/annonc/mdq033. Epub 2010 Feb 12.

PMID:
20154304
33.

A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy.

Billy F, Ribba B, Saut O, Morre-Trouilhet H, Colin T, Bresch D, Boissel JP, Grenier E, Flandrois JP.

J Theor Biol. 2009 Oct 21;260(4):545-62. doi: 10.1016/j.jtbi.2009.06.026. Epub 2009 Jul 15.

PMID:
19615383
34.

Chemotherapy may be delivered based on an integrated view of tumour dynamics.

Ribba B, You B, Tod M, Girard P, Tranchand B, Trillet-Lenoir V, Freyer G.

IET Syst Biol. 2009 May;3(3):180-90. doi: 10.1049/iet-syb.2008.0104.

PMID:
19449978
35.

[Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment].

Tranchand B, Falandry C, You B, Girard P, Ribba B, Tod M, Freyer G.

Bull Cancer. 2008 May 28;95 FMC Onco:F21-7. doi: 10.1684/bdc.2007.0541. French.

PMID:
18511363
36.

Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.

You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, Souquet PJ, Court-Fortune I, Trillet-Lenoir V, Fournel C, Tod M, Freyer G.

Lung Cancer. 2008 Nov;62(2):261-72. doi: 10.1016/j.lungcan.2008.03.008. Epub 2008 Apr 28.

PMID:
18442869
37.

Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy.

You B, Perrin P, Freyer G, Ruffion A, Tranchand B, Hénin E, Paparel P, Ribba B, Devonec M, Falandry C, Fournel C, Tod M, Girard P.

Clin Biochem. 2008 Jul;41(10-11):785-95. doi: 10.1016/j.clinbiochem.2008.04.001. Epub 2008 Apr 11.

PMID:
18440312
38.

Modelling methodology in physiopathology.

Boissel JP, Ribba B, Grenier E, Chapuisat G, Dronne MA.

Prog Biophys Mol Biol. 2008 May;97(1):28-39. doi: 10.1016/j.pbiomolbio.2007.10.005. Epub 2007 Nov 17. Review.

PMID:
18199472
39.

An age-and-cyclin-structured cell population model for healthy and tumoral tissues.

Bekkal Brikci F, Clairambault J, Ribba B, Perthame B.

J Math Biol. 2008 Jul;57(1):91-110. Epub 2007 Dec 7.

PMID:
18064465
40.

A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents.

Ribba B, Saut O, Colin T, Bresch D, Grenier E, Boissel JP.

J Theor Biol. 2006 Dec 21;243(4):532-41. Epub 2006 Jul 21.

PMID:
16930628
41.

QxDB: a generic database to support mathematical modelling in biology.

Ribba B, Tracqui P, Boix JL, Boissel JP, Thomas SR.

Philos Trans A Math Phys Eng Sci. 2006 Jun 15;364(1843):1517-32.

PMID:
16766358
42.

A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies.

Ribba B, Colin T, Schnell S.

Theor Biol Med Model. 2006 Feb 10;3:7.

43.

Supplemental Content

Support Center